BioSpace News Archive

Maze Therapeutics today announced that management will present a company overview at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 11:30 a.m. ET.

Vistagen today announced that positive safety and exploratory efficacy data from its large Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of anxiety in adults with social anxiety disorder (SAD) were presented in a late-breaking poster presentation at the American Society for Clinical Psychopharmacology (ASCP) 2023 Annual Meeting taking place in Miami from May 30 through June 2, 2023.

Cadrenal Therapeutics, Inc. announced that the company will participate in investor and partnering meetings at the BIO International Convention being held June 5-8, 2023 in Boston.

Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.

Penumbra, Inc. announced the U.S. Food and Drug Administration clearance and launch of Lightning Bolt™ 7, the most advanced and powerful arterial thrombectomy system on the market.

The National Comprehensive Cancer Network® announced the signing of a Memo of Understanding with Vietnam National Cancer Hospital and the Vietnam Cancer Association to work together to improve standards for cancer care throughout the country.

Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics.

Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC) has granted approval of BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.